Skip to main content
Apontis Pharma AG logo

Apontis Pharma AG — Investor Relations & Filings

Ticker · APPH ISIN · DE000A3CMGM5 LEI · 894500ETO1J6MR8PDF91 F Manufacturing
Open in API
Filings indexed 114 across all filing types
Latest filing 2024-03-28 Earnings Release
Country DE Germany
Listing F APPH

About Apontis Pharma AG

https://apontis-pharma.de/en/

Apontis Pharma AG is a pharmaceutical company that specializes in the development, marketing, and distribution of 'Single Pills'. These are fixed-dose combination drugs that unite two or three active pharmaceutical ingredients into a single tablet. The company's portfolio primarily focuses on treating cardiovascular diseases and other chronic conditions. By simplifying treatment regimens, the Single Pill approach aims to improve patient adherence and therapy outcomes, offering medical and economic benefits to the healthcare system. Apontis Pharma also engages in co-marketing activities for established pharmaceutical products.

Recent filings

Filing Released Lang Actions
APONTIS PHARMA expects profitable growth again in 2024
Earnings Release Classification · 1% confidence The document is a news release dated March 28, 2024, titled "APONTIS PHARMA expects profitable growth again in 2024". It explicitly mentions key financial figures for the 2023 financial year (sales, EBITDA, net result) and provides a forecast for 2024. It also contains tables summarizing Group figures, Income Statement, Balance Sheet, and Cash Flow Statement for 2023 vs 2022. The text states: 'APONTIS PHARMA AG (Ticker [APPH] / ISIN [DE000A3CMGM5] ), a leading pharmaceutical company specializing in Single Pill combinations in the German market, today presented its 2023 annual report.' Although it discusses the annual results, the format is that of a press release announcing these results, not the full, formal 10-K filing itself. Furthermore, it explicitly mentions a webcast/teleconference to explain the results and provides a link to the '2023 Annual Report' on the company website, suggesting this document is the announcement of the report rather than the report itself. This aligns best with the 'Earnings Release' (ER) category, which covers the initial announcement of periodical financial results (key highlights). It is more detailed than a typical ER but lacks the comprehensive structure of a 10-K. Given the focus on presenting the full year's results and outlook in a news format, ER is the most appropriate classification, although it borders on MDA (Management Discussion & Analysis) due to the detail, ER is standard for initial result announcements. FY 2023
2024-03-28 English
Jahresabschluss 2023
Audit Report / Information Classification · 1% confidence The document is titled "GESCHÄFTSBERICHT 2023" (Business Report 2023) and contains a detailed Table of Contents listing sections like 'KONZERNLAGEBERICHT' (Group Management Report), 'KONZERNABSCHLUSS' (Consolidated Financial Statements), 'Konzern-Bilanz' (Consolidated Balance Sheet), 'Konzern-Gewinn- und Verlustrechnung' (Consolidated Income Statement), and 'BESTÄTIGUNGSVERMERK' (Auditor's Report). The length (284,964 characters) is substantial, indicating a comprehensive annual filing rather than a brief announcement. The content structure aligns perfectly with a full Annual Report, which in the US context is equivalent to a 10-K, but given the German language and structure, it is best classified as a comprehensive Annual Report (AR) or, if the context implies the primary annual filing equivalent, 10-K. Since '10-K' is specifically defined as the 'Official yearly report covering company activity and full financial performance,' and this document clearly is that, '10-K' is the most appropriate code, even if the document is a German 'Geschäftsbericht'. If 'AR' (Audit Report / Information) is interpreted strictly as *standalone* audit reports, the comprehensive nature points to the full annual filing. FY 2023
2024-03-28 German
Annual financial statements 2023
Annual Report Classification · 1% confidence The document is explicitly titled 'ANNUAL REPORT 2023' and contains a comprehensive table of contents covering the Letter of the Management Board, Group Management Report, Consolidated Financial Statements, and the Certificate of the Independent Auditor. It provides detailed financial and operational performance data for the fiscal year 2023, fitting the definition of an Annual Report (10-K). FY 2023
2024-03-28 English
Jahresabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
Audit Report / Information Classification · 1% confidence The document is titled "Jahresabschluss zum 31. Dezember 2022" (Annual Financial Statements as of December 31, 2022) and contains detailed comparative balance sheets ("Bilanz") for 2022 and 2021, notes to the financial statements ("Anhang"), and a concluding statement by the management board ("Schlusserklärung des Vorstandes"). The content clearly represents a full set of annual financial statements prepared according to German commercial law (HGB). This aligns perfectly with the definition of an Annual Report, which in the US context is typically filed as a 10-K, but given the German context and the comprehensive nature of the financial statements provided, the closest equivalent in the provided list is the Annual Report (10-K), as it is the definitive yearly financial performance document. It is the report itself, not an announcement of the report (RPA). FY 2022
2024-02-26 German
APONTIS PHARMA successfully completes performance and efficiency improvement program
Earnings Release Classification · 1% confidence The document is a news release dated February 6, 2024, announcing the successful completion of a 'performance and efficiency improvement program,' including headcount reduction and cost savings. It details strategic changes (new go-to-market approach) and mentions an upcoming webcast and the date for the full 2023 financial figures release (March 28, 2024). This structure—a formal announcement of internal strategic/operational changes, often using keywords like 'Restructure of Company' (as seen in the metadata tags) and providing operational updates rather than full financial statements—is characteristic of a general corporate announcement. Since it is not a full Annual Report (10-K), an Interim Report (IR), an Earnings Release (ER) with results, or a specific regulatory filing like DIRS or DIV, it fits best under the general Regulatory Filings (RNS) category, which serves as a broad category for official corporate news releases that don't fit narrower definitions. It is not an RPA because it contains substantial detail about the program completion, not just an announcement that a report is available. FY 2023
2024-02-06 English
APONTIS PHARMA presents details of the restructuring and efficiency program Nine-month figures for 2023 and new sales and earnings forecast for 2023 published
Earnings Release Classification · 1% confidence The document explicitly states it presents 'Nine-month figures for 2023' and includes condensed financial statements (Income, Balance Sheet, Cash Flows) for the 9M 2023 period compared to 9M 2022. The keyword 'Quarterly / Interim Statement' is also present. This content structure is characteristic of a comprehensive report covering a period shorter than a full year, which aligns with the definition of an Interim / Quarterly Report (IR). Although it contains an earnings forecast update, the primary focus is the detailed financial reporting for the nine-month period, making IR the most accurate classification over a simple Earnings Release (ER). The document is substantial (over 16k characters) and contains the full figures, not just an announcement of the report's release. 9M 2023
2023-11-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.